PL Chip for T-TAS 01(IVD)

Thrombosis and bleeding management is an important consideration in several clinical situations:

  • Trauma
  • Surgery
  • Interventional procedures
  • Bleeding clinic

The T-TAS 01 System with PL chip is a reliable tool for measuring the overall primary hemostatic ability of the patient. An assessment of overall primary hemostasis (platelet thrombus formation) can help guide more informed decisions by providing information to determine whether the ability to form a platelet thrombus is impaired. Information about overall primary hemostatic ability is useful when evaluating:

  • Whether impaired platelet activity may be contributing to active bleeding
  • Whether a patient might benefit from a platelet transfusion
  • Whether primary hemostasis has returned to normal prior to surgery
  • Whether platelet activity has been significantly impaired in association with interventional procedures


Characteristics of the PL Chip assay:

  • Single-use microchip (PL Chip) produced by a high-precision injection molding
  • Small amount of whole blood sample (320 μl)
  • Quantitatively monitoring system by flow pressure waveform
  • Easy operation controlled by a dedicated computer with touch screen display

Assay principle

The T-TAS 01 System with PL chip is the first easy-to-use system for measuring primary hemostasis using a flow-based microchip. Some platelet assays use super-physiological concentrations of platelet activators (agonists) and artificial matrices to produce platelet activation and aggregation. The T-TAS 01 PL chip uses only arterial shear stress over a collagen-coated surface to produce platelet activation and aggregation. The combination of arterial shear stress and platelet adhesion to collagen allows the T-TAS system to more closely mimic in vivo primary hemostasis. Unlike other methods, which use a single aperture that becomes occluded, the T-TAS 01 PL chip contains 26 collagen-coated microcapillaries that normalize variability by providing a measurement of average occlusion across several channels.

Similar to when a blood vessel is damaged, as whole blood travels across the collagen-coated capillaries at arterial shear stresses, von-Willebrand factor-mediated attachment of platelets to the collagen surface occurs. Attached platelets become activated and release agonists that recruit and activate other platelets to the attachment site, resulting in platelet thrombus formation and growth.

As the platelet thrombus grows, the microcapillaries gradually become occluded. This occlusion is measured by the T-TAS 01 instrument as an increase in flow pressure. When there is a defect in primary hemostatic ability, such as when a patient is taking antiplatelet therapy, has von Willebrand disease, or has an inherited or acquired defect in primary hemostatic ability, occlusion of the capillaries is reduced.


Flow pressure analysis

When blood flows through the analytical path of the PL Chip, platelets adhere and aggregate on the surface of the collagen-coated capillary channels. The platelet aggregates gradually increase in size and eventually occlude the capillary, resulting in an increase of flow pressure. Thus, changes in flow pressure patterns reflect the platelet thrombus formation process.


Definitions of the parameters used for quantification of the platelet thrombus formation process

Only one specific term, AUC, is used to quantify platelet thrombus formation inside the PL Chip.

AUC (area under the flow pressure curve for 10 min) represents total thrombogenicity and reflects onset time, as well as growth and stability, of formed thrombi.


Measurement screen of PL Chip assay

T-TAS products are available for research use only in the United States Copyright © 2019 FUJIMORI KOGYO CO.,LTD. All Rights Reserved.